MedPath

Tagged News

AI Support Significantly Improves HER2 Scoring Accuracy in Breast Cancer Diagnosis

AIPrecision MedicineOncology
• A new study published in JCO Precision Oncology demonstrates that Ibex Medical Analytics' AI technology significantly improves pathologists' accuracy and consistency in HER2 biomarker scoring for breast cancer.
• The multi-center study showed AI-assisted pathologists achieved higher inter-observer agreement (83.7% vs 75%) and improved accuracy in identifying challenging HER2-low cases, which is critical for determining eligibility for new targeted therapies.
• The "zero-click" decision support tool demonstrated exceptional robustness across multiple labs, antibodies, scanners, and patient demographics, offering particular value in distinguishing between HER2 0 and 1+ cases.

GV20 Therapeutics Reports First Clinical Data for AI-Designed Checkpoint Inhibitor GV20-0251 in Advanced Solid Tumors

Monoclonal AntibodyOncologyAI
  • GV20 Therapeutics presented Phase 1 data for GV20-0251, marking the first clinical results for an AI-designed antibody targeting an AI-predicted immune checkpoint IGSF8.
  • The study enrolled 38 heavily pre-treated patients and demonstrated favorable safety with no dose-limiting toxicities across all dose levels from 0.5 to 20 mg/kg.
  • Two confirmed partial responses were observed in 12 evaluable metastatic cutaneous melanoma patients, with 14 of 29 patients showing stable disease including tumor shrinkage.
  • The drug showed dose-proportional pharmacokinetics with a 25.6-day half-life and full target occupancy on circulating T cells at doses ≥3 mg/kg.

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

NCT05669430RecruitingPhase 1
GV20 Therapeutics
Posted 3/23/2023

Global Breast Cancer Therapeutics Market Expected to Reach $78.61 Billion by 2033

OncologyTargeted TherapyMonoclonal AntibodyAIPrecision MedicineDrug Approval
• The global breast cancer therapeutics market, valued at $32.93 billion in 2023, is projected to reach $78.61 billion by 2033, growing at a CAGR of 9.09% over the next decade.
• North America dominates the market with a 38.61% revenue share, driven by high breast cancer prevalence and presence of key pharmaceutical companies including Pfizer, Roche, and Novartis.
• Targeted therapies hold the largest market segment at 64.85%, with hormone receptor-positive treatments accounting for 66.97% of the market as precision medicine approaches gain traction.

China Dominates AI-Driven Drug Discovery Patent Landscape, Reshaping Pharmaceutical R&D

AIDrug Discovery
  • China has filed over 38,000 generative AI patent applications between 2014-2023, with a significant portion focused on drug discovery and compound screening technologies.
  • The surge in Chinese AI pharmaceutical patents is fueled by government investment, tech giant participation, pharmaceutical market growth, and access to vast healthcare data resources.
  • AI-driven drug discovery systems being patented can analyze chemical compounds, predict properties, and identify drug candidates more efficiently, potentially reducing development timelines and costs.

Transgene Advances Personalized Cancer Vaccine TG4050 to Phase II Trial in Head and Neck Cancer

AI
  • Transgene has enrolled the first patient in the Phase II portion of its randomized Phase I/II trial evaluating TG4050, an individualized therapeutic cancer vaccine for head and neck cancer treatment.
  • Phase I data showed promising results with all treated patients remaining disease-free after a median follow-up of 18.6 months, while only control arm patients experienced relapse.
  • TG4050 represents the only individualized neoantigen cancer vaccine currently being developed in a randomized trial for adjuvant treatment of head and neck cancer.
  • The trial aims to enroll approximately 80 patients internationally, with completion of Phase II enrollment expected by Q4 2025.

A Clinical Trial Evaluating TG4050 in Head and Neck Cancer

NCT04183166Active, Not RecruitingPhase 1
Transgene
Posted 12/12/2019

AI-Driven Drug Discovery Accelerates with New Academic Alliance Targeting Protein Kinases

AIDrug Discovery
  • The Lamarr Institute, b-it, and TüCAD2 have formed a collaborative alliance to accelerate drug discovery using artificial intelligence, focusing specifically on protein kinase inhibitors that could treat cancer, neurological disorders, and autoimmune diseases.
  • The partnership combines AI expertise in data analysis and machine learning from German research institutions with medicinal chemistry capabilities, utilizing the world's largest academic collection of 12,000 protein kinase inhibitors.
  • AI technologies are revolutionizing drug discovery by reducing development timelines from 10-15 years and costs reaching billions of dollars, with applications spanning virtual screening, toxicity prediction, and de novo drug design.
  • The collaboration emphasizes "Explainable AI" to ensure transparency and acceptance in medical applications, addressing the critical need for interpretable machine learning in pharmaceutical research.

Xaira Therapeutics Launches with Record $1 Billion Funding to Revolutionize AI-Driven Drug Discovery

AIDrug Discovery
  • Xaira Therapeutics launched with $1 billion in funding from ARCH Venture Partners and other major investors, marking the largest initial commitment in ARCH's nearly 40-year history.
  • The company aims to leverage generative AI and foundational models from the University of Washington's Institute of Protein Design to create drugs that were previously impossible to develop.
  • Former Stanford president and Genentech CSO Marc Tessier-Lavigne leads the company as CEO, with investors expressing confidence despite his recent resignation from Stanford following research data manipulation allegations at his former lab.
  • The funding reflects growing industry investment in generative AI for drug discovery, with the technology showing potential to optimize every stage of pharmaceutical R&D from target discovery to commercialization.

AI-Assisted Colonoscopy Boosts Adenoma Detection Rate by 40% in Junior Endoscopists

AI
  • CU Medicine research demonstrates that AI-assisted colonoscopy significantly improves adenoma detection rates by 40% among junior endoscopists with less than three years of experience.
  • The study involved 766 patients and 22 junior endoscopists-in-training, showing particularly impressive performance improvements among beginners, addressing a critical gap in endoscopic training.
  • Researchers have also developed AI-Endo, an innovative AI surgical platform that guides surgeons through endoscopic submucosal dissection (ESD) procedures for early-stage gastrointestinal cancer treatment.

First Fully AI-Generated Drug Enters Phase II Clinical Trials for Idiopathic Pulmonary Fibrosis

AIDrug DiscoveryRare Disease
  • Insilico Medicine's INS018_055 becomes the first drug with both AI-discovered target and AI-generated design to reach Phase II clinical trials for idiopathic pulmonary fibrosis treatment.
  • The drug development process took just 30 months from target discovery to Phase I trials, approximately half the time of traditional drug discovery methods.
  • IPF affects about 100,000 people in the U.S. and typically leads to death within 2-5 years if untreated, with current treatments only slowing disease progression.
  • The Phase II trial is a randomized, double-blind, placebo-controlled study over 12 weeks in China, with plans to expand to 60 subjects across 40 sites in the U.S. and China.

Tempus Receives First FDA Clearance for AI-Based Atrial Fibrillation Risk Detection Algorithm

AIPrecision Medicine
  • Tempus received FDA 510(k) clearance for its Tempus ECG-AF device, marking the first FDA clearance for an atrial fibrillation indication in the cardiovascular machine learning-based notification software category.
  • The AI-based algorithm uses electrocardiogram data to help identify patients who may be at increased risk of atrial fibrillation and flutter.
  • This regulatory milestone represents a significant advancement in AI-enabled cardiovascular risk assessment and precision medicine applications.
  • The clearance positions Tempus to expand its AI capabilities beyond oncology into cardiovascular disease detection and prevention.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.